GeoVax Labs, Inc. – NASDAQ:GOVX
GeoVax Labs stock price today
$0.735
-1.72
-70.13%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 4 minutes
GeoVax Labs stock price monthly change
-11.51%
month
GeoVax Labs stock price quarterly change
-11.51%
quarter
GeoVax Labs stock price yearly change
+559.52%
year
GeoVax Labs key metrics
Market Cap | 20.52M |
Enterprise value | N/A |
P/E | -0.82 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | 51.70 |
Price/Book | 0.15 |
PEG ratio | -0.03 |
EPS | -14.45 |
Revenue | N/A |
EBITDA | -28.27M |
Income | -27.77M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -22925.62% |
Oper. margin | -22936.36% |
Gross margin | 0% |
EBIT margin | -22936.36% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeGeoVax Labs stock price history
GeoVax Labs stock forecast
GeoVax Labs financial statements
| Jun 2023 | 0 | -5.92M | |
|---|---|---|---|
| Sep 2023 | 0 | -8.40M | |
| Dec 2023 | 103.91K | -7.59M | -7306.57% |
| Mar 2024 | 0 | -5.85M |
| 2025 | 24.3M | -25.8M | -106.17% |
|---|---|---|---|
| 2026 | 133.49M | -5.19M | -3.89% |
| 2027 | 26.86M | 1.99M | 7.44% |
| 2028 | 63.83M | -2.01M | -3.16% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 21249062 | 4.08M | 19.23% |
|---|---|---|---|
| Sep 2023 | 16201031 | 7.08M | 43.71% |
| Dec 2023 | 9283219 | 3.51M | 37.92% |
| Mar 2024 | 3358182 | 3.30M | 98.38% |
| Jun 2023 | -6.03M | -23.80K | 0 |
|---|---|---|---|
| Sep 2023 | -5.09M | -6.19K | 0 |
| Dec 2023 | -10.27M | -18.94K | 4.06M |
| Mar 2024 | -5.68M | 0 | 0 |
GeoVax Labs alternative data
| Aug 2023 | 14 |
|---|---|
| Sep 2023 | 14 |
| Oct 2023 | 14 |
| Nov 2023 | 14 |
| Dec 2023 | 14 |
| Jan 2024 | 14 |
| Feb 2024 | 14 |
| Mar 2024 | 17 |
| Apr 2024 | 17 |
| May 2024 | 17 |
| Jun 2024 | 17 |
| Jul 2024 | 17 |
GeoVax Labs other data
8.06%
-26.91%
of GOVX is owned by hedge funds
491.66K
-1.64M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Apr 2023 | 40000 | 0 |
| Aug 2023 | 45087 | 0 |
| Sep 2023 | 9653 | 0 |
| Dec 2023 | 13888 | 0 |
| Feb 2024 | 2000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | REYNOLDS MARK officer: CFO | Common Stock | 2,000 | $2.77 | $5,540 | ||
Purchase | MCKEE KELLY T. JR. officer: Chief Medical Officer | Common Stock | 13,888 | $0.36 | $5,000 | ||
Purchase | MCKEE KELLY T. JR. officer: Chief Medical Officer | Common Stock | 9,653 | $0.52 | $5,020 | ||
Purchase | DODD DAVID A director, officer.. | Common Stock | 35,087 | $0.57 | $20,000 | ||
Purchase | REYNOLDS MARK officer: CFO | Common Stock | 10,000 | $0.52 | $5,180 | ||
Purchase | DODD DAVID A director, officer.. | Common Stock | 32,000 | $0.64 | $20,448 | ||
Purchase | REYNOLDS MARK officer: CFO | Common Stock | 8,000 | $0.63 | $5,040 | ||
Purchase | CHASE RANDAL D director | Common Stock | 10,000 | $1.1 | $11,000 | ||
Purchase | SHARKEY JOHN W. officer: VP, Business Development | Common Stock | 1,000 | $0.82 | $820 | ||
Purchase | MCKEE KELLY T. JR. officer: Chief Medical Officer | Common Stock | 4,464 | $1.12 | $5,000 |
| Quarter | Transcript |
|---|---|
| Q1 2024 14 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 1 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 8 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 9 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. David Alan Dodd (1950) Chairman, Pres & Chief Executive Officer | $420,980 |
Mr. Mark W. Reynolds CPA, CPA (1962) Chief Financial Officer & Corporation Sec. | $357,390 |
| Dr. Mark J. Newman Ph.D. (1955) Chief Scientific Officer | $137,080 |
-
What's the price of GeoVax Labs stock today?
One share of GeoVax Labs stock can currently be purchased for approximately $0.73.
-
When is GeoVax Labs's next earnings date?
Unfortunately, GeoVax Labs's (GOVX) next earnings date is currently unknown.
-
Does GeoVax Labs pay dividends?
No, GeoVax Labs does not pay dividends.
-
How much money does GeoVax Labs make?
GeoVax Labs has a market capitalization of 20.52M.
-
What is GeoVax Labs's stock symbol?
GeoVax Labs, Inc. is traded on the NASDAQ under the ticker symbol "GOVX".
-
What is GeoVax Labs's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of GeoVax Labs?
Shares of GeoVax Labs can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are GeoVax Labs's key executives?
GeoVax Labs's management team includes the following people:
- Mr. David Alan Dodd Chairman, Pres & Chief Executive Officer(age: 75, pay: $420,980)
- Mr. Mark W. Reynolds CPA, CPA Chief Financial Officer & Corporation Sec.(age: 63, pay: $357,390)
- Dr. Mark J. Newman Ph.D. Chief Scientific Officer(age: 70, pay: $137,080)
-
How many employees does GeoVax Labs have?
As Jul 2024, GeoVax Labs employs 17 workers.
-
When GeoVax Labs went public?
GeoVax Labs, Inc. is publicly traded company for more then 5 years since IPO on 25 Sep 2020.
-
What is GeoVax Labs's official website?
The official website for GeoVax Labs is geovax.com.
-
Where are GeoVax Labs's headquarters?
GeoVax Labs is headquartered at 1900 Lake Park Drive, Smyrna, GA.
-
How can i contact GeoVax Labs?
GeoVax Labs's mailing address is 1900 Lake Park Drive, Smyrna, GA and company can be reached via phone at +678 3847220.
GeoVax Labs company profile:
GeoVax Labs, Inc.
geovax.comExchange:
NASDAQ
Full time employees:
17
Industry:
Biotechnology
Sector:
Healthcare
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
1900 Lake Park Drive
Smyrna, GA 30080
Smyrna, GA 30080
CIK: 0000832489
ISIN: US3736786068
CUSIP: 373678507
